China, the great concern December 20, 2023 4Asia The month of December began in Washington with the meeting of the International Democratic Union (IDU, International Democracy Union)... Marco Rubio, Republican senator for the State of Florida, closed the. ..
Condemn Campus Antisemitism, But Don’t Stop There U.S. Senator Marco Rubio (R-FL) December 21, 2023 The Federalist …On one hand, it is a welcome sign of cultural sanity when elites rebuke pro-terrorist protestors and deplorably weak administrators at our most... Labour Tens Machines
A recent report revealed that Brite Semiconductors, a Chinese company with ties to the Chinese Communist Party (CCP) and People’s Liberation Army, uses U.S. technology to design chips. The U.S. must prevent China from using American chip-design software to advance its...
U.S. Senator Marco Rubio (R-FL) released a report detailing his 2023 accomplishments. “This was a year of economic hardship and social turmoil. It’s far from the first time Americans have seen such upheaval, but familiar doesn’t mean easy. “As Floridians grapple with...
Dec 20, 2023 |Press Releases, Press Releases
In July 2019, Alex Saab, a Colombian money launderer, was charged for his role in a bribery scheme for the criminal Maduro narco-regime. President Biden has granted another concession to Maduro with the release of Saab. As we have witnessed throughout this...
Japan-based Nippon Steel Corporation is set to acquire U.S. Steel Corporation, one of America’s leading steel companies, despite alternative offers from multiple American steel companies and consortiums of investors. The steel industry remains critical to the United...
The U.S. Food and Drug Administration (FDA) relies on foreign entities, like China, for many of our critical drugs and medical devices. American companies use foreign facilities to drive down costs, but many of these facilities have vastly lower production quality and safety standards. This puts Americans at risk of drug shortages and endangers their health.
U.S. Senator Marco Rubio (R-FL) and colleagues sent a letter to FDA Commissioner Robert Califf criticizing the agency’s standards of foreign drug and medical device production and requested information about how the FDA intends to increase the frequency of inspections abroad.
Joining Rubio were Senators Cindy Hyde-Smith (R-MS), Marsha Blackburn (R-TN), Mike Braun (R-IN), Pete Ricketts (R-NE), Josh Hawley (R-MO), Eric Schmitt (R-MO), Roger Wicker (R-MS), and James Lankford (R-OK).
The full text of the letter is below.
We write with regard to the U.S. Food and Drug Administration’s (FDA) foreign inspection criteria and process. For decades, Americans have trusted the FDA to ensure that medications and medical devices made abroad are safe to use. However, multiple cases of unsafe and unhygienic foreign products and production facilities call into question whether the FDA is holding foreign manufacturers to the same quality and safety standards it imposes on domestic facilities. Lax and infrequent inspections of foreign facilities threaten patients, while also threatening domestic producers that are held to a higher standard.
Pursuant to section 374(h)(1) of the Federal Food, Drug, and Cosmetic Act, drugs manufactured in foreign countries, and intended for use in the United States, must meet the same statutory and regulatory requirements as drugs produced in the United States. This is far from the case today. The Food, Drug, and Cosmetic Act requires the FDA to inspect domestic and foreign establishments using a risk-based schedule, weighing how often the agency inspects facilities based on a set of risk factors such as compliance history, the inherent risk of manufacturing the drug or device, and the plant’s history of recalled products. Yet, agency data shows that FDA completed only eight inspections of Chinese drug manufacturers and zero of Chinese device manufacturers in 2022. Meanwhile, the FDA completed 897 inspections of domestic drug manufacturers and 1,706 inspections of domestic device manufacturers in 2022. It is of course critical that every drug and device manufacturer, foreign or domestic, receives timely, thorough inspections. But the FDA’s inspection records show a clear and perverse disparity. In effect, the FDA is treating American producers as if they are orders of magnitude more risky than foreign producers, when the opposite is plainly true.
Americans are frequently endangered by low quality and unsafe drugs and devices manufactured abroad. Earlier this month, Cardinal Health recalled 32 million of its Chinese syringes due to a manufacturing error that could have caused patients to overdose or underdose. Similarly, valsartan, a drug commonly used for high blood pressure and heart failure, was recalled in 2018 because the manufacturer of the drug’s active pharmaceutical ingredient (API) in China changed its manufacturing processes without a formal risk assessment, leading to an impurity suspected of causing cancer to contaminate the drugs. This recall led to more than half of all valsartan products to be pulled from shelves.
Americans deserve to have confidence that the drugs and devices they purchase will improve their health, whether they were produced here or abroad. We must also ensure that foreign manufacturers are held to the same standard as domestic manufacturers to avoid putting our workers and factories at a disadvantage in the global market. It is clear that the FDA is not taking adequate steps to ensure a level playing field for American industry. Therefore, we respectfully request that you provide answers to the following questions:
Medical Apparatus Thank you for your attention to this matter. We look forward to your prompt response.